A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
Part of paid clinical trials in Miami, Florida.
- Sponsor
- Pfizer
- Study ID
- NCT07231991
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Healthy Participants
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Accepted
Interventions
- vepdegestrant — DRUGVepdegestrant administered as a single oral 200 mg dose
Study Details
The purpose of the study is to look at how the body processes a study medicine called vepdegestrant in participants with loss of liver function relative to people with normal liver function. This study is seeking participants who are: * females who cannot have children or males * between 18 and 70 years of age * weigh more than 50 Kilograms (110 pounds) * either healthy with normal liver function or have loss of liver function All participants in this study will take one dose of vepdegestrant by mouth. This study looks at how the medicine is changed and removed from the body after being taken by the participants. The amount of vepdegestrant in participants with loss of liver function will be compared to the amount of vepdegestrant in participants with normal liver function. All participants will stay at the study clinic for about 11 days and 10 nights.
Key Dates
- Start date
- Nov 18, 2025
- Status verified
- Mar 2026
- Primary completion
- Dec 4, 2026
- Completion
- Dec 23, 2026
Study Design
- Enrollment
- 24 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Experimental: Group 1participants with normal hepatic function
- Experimental: Group 2participants with moderate hepatic impairment
- Experimental: Group 3participants with severe hepatic impairment
Primary Outcome Measure
Maximum observed concentration (Cmax) for vepdegestrant [ Time Frame: Pre-dose, and 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, and 216 hours post dose ]
Central Contacts
- Pfizer CT.gov Call Center1-800-718-1021
Locations (4)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Clinical Pharmacology of Miami | Miami | Florida | 33172 | - |
| Floridian Clinical Research, LLC | Miami Lakes | Florida | 33016 | - |
| Orlando Clinical Research Center | Orlando | Florida | 32809 | - |
| Genesis Clinical Research, LLC | Tampa | Florida | 33603 | - |
Find similar trials in Miami, FL
Related Studies
- FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and PatientsPHASE1 · Recruiting · Pfizer · Anaheim, California
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With DyslipidemiaPHASE1 · Recruiting · AstraZeneca · Glendale, California
- A Study to Learn About a Vaccine Against E Coli in Healthy AdultsPHASE1 · Recruiting · Pfizer · Anaheim, California
- The Increasing Mindfulness Engagement ProjectRecruiting · Florida State University · Tallahassee, Florida